Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease

BACKGROUND: Falls are a common complication of Parkinson’s disease. There is a need for new therapeutic options to target this debilitating aspect of the disease. Cholinergic deficit has been shown to contribute to both gait and cognitive dysfunction seen in the condition. Potential benefits of usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Neumann, S., Taylor, J., Bamford, A., Metcalfe, C., Gaunt, D. M., Whone, A., Steeds, D., Emmett, S. R., Hollingworth, W., Ben-Shlomo, Y., Henderson, E. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556953/
https://www.ncbi.nlm.nih.gov/pubmed/34715821
http://dx.doi.org/10.1186/s12883-021-02430-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556953/
https://www.ncbi.nlm.nih.gov/pubmed/34715821
http://dx.doi.org/10.1186/s12883-021-02430-2

Ejemplares similares